Drugs / [11C]osimertinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03463525 | Oct 2018 → Mar 2020 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]osimertinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03463525 ↗ |
| Route | Intravenous | “3 single IV microdose administrations” NCT03463525 ↗ |